Filter by:
Revita
ADA, 2023
Glycemic Improvement, Insulin Reductions, and Improved Body Weight 48 Weeks after Revita Duodenal Mucosal Resurfacing in T2D patients with Previously Inadequately Controlled Glucose Despite Multiple Glucose-Lowering Agents Including Insulin
Fonseca, et al. presented poster at American Diabetes Association 2023, San Diego, CA, June 2023
Revita
DDW, 2023
Duodenal Mucosal Resurfacing Procedure Training and Implementation
Galvani, et al. presented poster at Digestive Disease Week (DDW) 2023, Chicago, IL USA, May 2023
Rejuva
ASGCT, 2023
A Pancreatic Gene Therapy Delivery Platform for the Treatment of Type 2 Diabetes
Rajagopalan, et al. presented at American Society of Gene and Cell Therapy, Los Angeles, CA, May 2023
Rejuva
ASGCT, 2023
Local Delivery and Tissue Restricted Expression to Optimize Therapeutic Profile for Pancreatic Gene Therapy
Rajagopalan, et al. presented at American Society of Gene and Cell Therapy, Los Angeles, CA, May 2023
Rejuva
WCIRDC, 2022
AAV-Mediated Pancreatic Gene Therapy for Type 2 Diabetes
Liou, et al. presented at World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC), Universal City, CA, Dec 2022
Revita
UEGW, 2022
Enhanced β-cell function and improved insulin sensitivity after Revita® Duodenal Mucosal Resurfacing in patients with T2D
Busch, et al. presented poster at United European Gastroenterology Week (UEGW), Vienna, Austria, Oct 2022
Revita
DDW, 2022
Improvements In Insulin Sensitivity Seen In Patients With Type 2 Diabetes After Revita® DMR Are Associated With A Decrease In Glucagon, Glucose, And GIP After A Mixed Meal Tolerance Test
Meiring, et al. presented at Digestive Disease Week (DDW) 2022, San Diego, CA, USA, May 2022
Revita
Cardiovascular Diabetology
Eliminating exogenous insulin therapy in patients with type 2 diabetes by duodenal ablation and GLP-1 RA decreases risk scores for cardiovascular events
Meiring, et al.
Revita
Diabetes Research and Clinical Practice, 12 January 2022
Durable metabolic improvements 2 years after duodenal mucosal resurfacing (DMR) in patients with type 2 diabetes (REVITA-1 Study)
van Baar, et al.